It is well known that New Jersey’s medical marijuana program was significantly hindered by Governor Christie. Since taking office, Governor Murphy has sought to significantly expand the program by expanding the list of qualifying medical conditions, significantly cutting the registration fees for patients, and expanding the number of doctors who can prescribe medical marijuana. The State even launched a new program that allows patients and doctors to register with the medical marijuana program through their mobile devices.
Governor’s Murphy’s efforts have paid ...
There are many reasons why Governor Murphy has prioritized legalizing marijuana, but perhaps the most important reason is the social justice aspect. An article posted on NJ.com yesterday displayed statistics about marijuana arrests in each state that were gathered from 2016 data from the FBI’s Uniform Crime Reporting program. According to the article’s analysis of the FBI data, New Jersey ranked third in the nation in total marijuana arrests, and second in the nation in marijuana arrest rate (arrests per 100,000 people).[1] Census data, however, reveals the New Jersey ...
Alan Silber a member of Pashman Stein Walder Hayden's Cannabis Law Group was extensively quoted in the Asbury Park Press article, "NJ Marijuana Legalization: Lawyers Say Weed is Good for You."
“So, you have a substance which you’re saying is illegal, which is identical to a substance that is made in the human body to keep us healthy,’’ Silber said. “What’s wrong with that picture?’’
He added, “Medical benefits from the use of marijuana not known in 1971, …and impediments to its lawful use as a result of its Schedule 1 classification, are abundant and glaringly ...
Registration For The Twelfth National Clinical Conference On Cannabis Therapeutics
Pashman Stein Walder Hayden P.C. Attorneys Alan Silber, CJ Griffin and Ronny Jo Siegal are set to present on in Jersey City on May 10th at The Twelfth National Clinical Conference on Cannabis Therapeutics hosted by Patients Out of Time.
The Pre-Conference Policy Workshop: Medical Cannabis in the States of Confusion is scheduled for Thursday, May 10, immediately prior to the conference. Patients Out of Time will offer a policy seminar featuring experts in law, science, and policies. This workshop is ...
De-Scheduling could have significant impact on how marijuana is regulated in New Jersey
Pashman Stein Walder Hayden filed a Brief De-Scheduling Marijuana today in support of the de-scheduling marijuana, and is in direct response to New Jersey’s Division of Consumer Affairs solicitation for public comment on how marijuana is classified under state law and whether any change in its classification status is warranted.
To reevaluate whether the currently accepted uses for medical marijuana warrant a change in its classification as a “Schedule I” drug in New Jersey, a ...
The New Jersey Division of Consumer Affairs is holding two public comment sessions scheduled on April 19th and April 24th which will be part of the process to re-evaluate, particularly in light of recent changes to this State’s policies on medical marijuana, whether marijuana should remain as a Schedule I drug under the New Jersey Controlled Dangerous Substances Act (the “CDSA”), or be re-classified to Schedule IV (or lower). Marijuana is currently a Schedule I controlled substance, which according to the CDSA means that it “(1) has high potential for abuse; and (2) has no ...
On March 28, 2018, the NJ Department of Health issued its report on medical marijuana in response to Gov. Murphy’s Executive Order Number 6. The Report suggests ways that the Department intends to modify the existing Administrative Code, which the Department can do without legislative changes, and makes some recommendations to the Legislature to adopt statutory changes. Governor Murphy then announced that most of the Administrative Code changes would become effective immediately.
Among the administrative changes the Department states that it intends to take immediately ...
On March 5, 2018, Assemblymen Gusciora and Eustace introduced new legislation (Assembly Bill, No. 3437) to revise New Jersey’s medical marijuana program. The proposed legislation would make substantial changes to the existing law and address many of the roadblocks that medical marijuana advocates have complained impeded New Jersey’s medical marijuana program.
The legislation would create three regions: northern, central and southern New Jersey and require at least six medical marijuana dispensaries and two cultivator-processors in each region. With the six existing ...
While there are many social justice benefits to legalizing recreational cannabis, the economic benefits cannot be overlooked. Studies show that Washington and Oregon had 22,952 and 11,295 full-time cannabis jobs, respectively. This is obviously a huge benefit to any economy, as nationwide it is estimated that the cannabis industry worth $10 billion dollars a year. Estimates suggest that New Jersey’s cannabis industry could easily be worth $1 billion per a year, which will reap considerable tax benefits for the state.
NJ Advance Media recently sent a reporter to Oregon and ...
A Federal judge in New York dismissed a lawsuit challenging the scheduling of marijuana as a class I drug. Several challenges to its classification had been brought in the past and all have been unsuccessful since marijuana was classified during the Nixon administration. This lawsuit sought to demonstrate that the classification was wrong because there are medical benefits from marijuana, which means it should not be classified as class I. The criteria for class 1 drugs includes that the drug has a high potential for abuse, no currently accepted medical use in treatment and a lack of ...
